What is LDN?
Our mission is to spread awareness of LDN......
LDN is short for Low dose naltrexone. Naltrexone is a drug that was approved by the FDA in 1985 to treat opiate dependence. It is marketed under the names, ‘Revia and Depade’, and in some countries (including the US), an extended-release formulation is available as ‘Vivitrol’. Naltrexone is commonly used at a 50 mg – 100 mg daily for treating opiate dependence.
The term LDN refers to the use of naltrexone at low doses; specifically between 3 mg and 10 mg per day and being used as an ‘off-label’ treatment. Naltrexone exhibits novel and paradox effects where administered at these low doses, as discovered by Ian S. Zagon and his team at Hershey Medical Center, Penn State University in 1980. Since the discovery, numerous laboratory and animal studies have been carried out to investigate the novel effects of LDN in cancer and autoimmune disorders.
The use of LDN for such diseases as cancer was first proposed by Ian Zagon, PhD, and LDN's broader clinical effects in humans were proposed by Bernard Bihari, MD.
LDN General Websites
“Low Dose Naltrexone (LDN) may well be the most important therapeutic breakthrough in over fifty years. It provides a new, safe and inexpensive method of medical treatment by mobilizing the natural defenses of one’s own immune system.
LDN substantially reduces health care costs and improves treatment of a wide array of diseases. Unfortunately, because naltrexone has been without patent protection for many years, no pharmaceutical company will bear the expense of the large clinical trials necessary for FDA approval of LDN’s new special uses. It is now up to public institutions to seize the opportunity that LDN offers.”
— David Gluck, MD
What is low-dose naltrexone and why is it important?
> Low-dose naltrexone holds great promise for the millions of people worldwide with autoimmune diseases or central nervous system disorders or who face a deadly cancer.
> In the developing world, LDN could provide the first low-cost, easy to administer, and side-effect-free therapy for HIV/AIDS.
Naltrexone itself was approved by the FDA in 1984 in a 50mg dose for the purpose of helping heroin or opium addicts, by blocking the effect of such drugs. By blocking opioid receptors, naltrexone also blocks the reception of the opioid hormones that our brain and adrenal glands produce: beta-endorphin and metenkephalin. Many body tissues have receptors for these endorphins and enkephalins, including virtually every cell of the body's immune system.
In 1985, Bernard Bihari, MD, a physician with a clinical practice in New York City, discovered the effects of a much smaller dose of naltrexone (approximately 3mg once a day) on the body's immune system. He found that this low dose, taken at bedtime, was able to enhance a patient's response to infection by HIV, the virus that causes AIDS. [Note: Subsequently, the optimal adult dosage of LDN has been found to be 4.5mg.]
In the mid-1990's, Dr. Bihari found that patients in his practice with cancer (such as lymphoma or pancreatic cancer) could benefit, in some cases dramatically, from LDN. In addition, people who had an autoimmune disease (such as lupus) often showed prompt control of disease activity while taking LDN.